Sai Life Sciences Ltd(SAILIFE)

NSE: SAILIFEBSE: 544306

₹ 1,395-0.07%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 29,632 crNext results: 5 Nov 2026Website: www.sailife.comUpdated: 24 Oct 2026

About

Sai Life Sciences is an innovator-focused contract research, development and manufacturing organisation (CRDMO) providing integrated small-molecule services from discovery through commercial supply. It is the only Indian CRDMO of scale combining both CRO and CDMO capabilities for small molecules, serving 18 of the top 25 global pharmaceutical companies. Revenue grew from ₹870 Cr in FY2022 to ₹2,242 Cr in FY2026, and the company completed its IPO in December 2024.^[1][2][3]

Business segments

CDMO (contract development and manufacturing) contributed ~60% of revenues in Q1 FY27, growing ~6% YoY; CRO (contract research) contributed ~40%, growing 26% YoY.^[4]
The company operates as a single reported segment - Contract Research, Development and Manufacturing (CRDMO) - for financial reporting purposes.^[1]

Operations and capacity

Manufacturing facilities at Bidar (Karnataka) and Bollaram (Hyderabad) are US FDA approved; R&D centres operate in Hyderabad, Boston, and Manchester.^[1][2]
Capacity utilisation was ~65% in Q1 FY27, up from ~60% in Q3 FY26.^[4][5]
A new 100,000 sq. ft. discovery R&D facility at Genome Valley, Hyderabad came on stream in Q1 FY27 and was already at full capacity upon opening.^[4]
Phase 2 expansion of the Vivarium at the Hyderabad R&D Centre completed in H1 FY26, doubling the preclinical assay footprint.^[6]
Scientific headcount as at 31 March 2025: 2,605 staff including 340 PhDs and 1,650 master's degree holders.^[1]

Key operating numbers

Active commercial molecules: 33 in Q1 FY27 (34 as at end of FY26 before one adjustment); 14 late-phase molecules in the pipeline as of Q1 FY27.^[4][7]
Consolidated revenue reached ₹554 Cr in Q1 FY27, +12% YoY vs ₹496 Cr in Q1 FY26.^[4]
Revenue from the top 19 large pharma clients expanded to 49% of total revenue in FY26, up from 28% in FY22.^[7]
New modalities (peptides, ADC payloads/linkers, oligonucleotides) contributed 4 - 5% of revenues in Q1 FY27.^[4]
USFDA inspection track record: 100% successful as of Q1 FY27.^[4]

Customers and distribution

Returning customers accounted for over 90% of revenue in both FY25 and FY26; ~65% of discovery customers are on integrated end-to-end service delivery as of Q1 FY27.^[4]
Top customer accounted for approximately 12% of total CRDMO revenues as of Q3 FY26; two customers each exceeded 10% of consolidated revenue in FY25.^[5][1]
Company has entered the veterinary API segment and partnered with three of the top five global animal health companies as of H1 FY26.^[6]

Expansion and capex

FY27 capex guidance of ₹1,100 - 1,300 Cr reaffirmed as of Q1 FY27, allocated approximately 75% to capacity expansion and 25% to capability building.^[4][7]
Capex incurred in Q1 FY27: ₹263 Cr.^[4]
450 KL of commercial manufacturing capacity being added at the Bidar facility across two blocks, targeted by end of FY27; total scale-up target is 1,150 KL by end of FY27.^[5][6]
Peptide commercial manufacturing facility planned at the Choutuppal greenfield site near Hyderabad, expected operational in 2028; total spend on peptide capabilities expected to be less than ₹300 Cr by end of 2028.^[4]
Small-molecule oral-solid formulation capability for Phase 1/2 clinical supplies (China+1 driven) expected to be operationally ready within FY27.^[4]

Pipeline and new modalities

Six late-phase molecules were added over the 15 months to Q1 FY27, five via large pharma FTE relationships; one top-tier pharma expanded into a full end-to-end discovery-to-commercial engagement.^[4]
First dedicated peptide development lab coming online for a top-tier pharma company; a GMP pilot facility for clinical peptide supplies is also coming online as of Q1 FY27.^[4]
XDC (antibody-drug conjugate) Centre of Excellence close to opening as of Q1 FY27; ADC bio-conjugation capabilities published in peer-reviewed journals.^[4]

Recent developments

CRISIL Ratings downgraded Sai Life Sciences' credit rating from 'AA' to 'A' with a negative outlook, reported in the exchange filing dated 7 August 2026 for the quarter ended 30 June 2026.^[8]
IPO completed in December 2024; proceeds of ₹7,200 million were used to fully repay outstanding borrowings, reducing the debt-equity ratio to 0.00 from 0.51.^[1]
FY26 saw 29% revenue growth, with CDMO up 33% and CRO up 24% YoY; EBITDA grew 56% YoY to reach a 30% margin for the full year.^[7]

Market Cap

₹29,632 Cr

High / Low

₹1,697 / 786

Stock P/E

81.5

Price / Book

11.9

Book Value

₹117

EPS

₹16.5

No. of Shares

21.18 Cr

ROCE

20.0%

ROE

15.1%

OPM

22.9%

Debt / Equity

0.04

Sales

₹2,192 Cr

Net Profit

₹349 Cr

Promoter holding

34.5%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials